Physician profile
Angela Park
NPI 1407349236
$826.21
in general payments reported to CMS, 2019-2025
12 companies · $98.37 in 2025
The $98.37 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.39 · 2022: $56.58 · 2023: $270 · 2024: $361 · 2025: $98.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.58 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $121.25 | 2022-2024 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $120.73 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.51 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $73.26 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $35.69 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $35.44 | 2025 | Trelegy Ellipta |
| Alkermes, INC. | $32.80 | 2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $14.70 | 2023 | Ingrezza |
| Almatica Pharma LLC | $14.44 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2022 | |
| Indivior INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.